Answers are grounded in this paper and cite their sources.
The volume of residual disease after cytoreductive surgery is the main prognostic factor that the surgical team can influence in advanced ovarian cancer. In the combined analysis of three randomized trials of the Arbeitsgemeinschaft Gynaekologische Onkologie – Ovarian Cancer Study Group (AGO-OVAR) and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO), median overall survival reached 99.1 months in patients without visible residual disease, compared with 36.2 months with residual disease of 1–10 mm and 29.6 months with residual disease larger than 10 mm [1].
No takes yet. Share an insight, caveat, or question.
Antoni Llueca (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: